Sequoia Financial Advisors LLC Increases Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Sequoia Financial Advisors LLC boosted its stake in shares of Genmab A/S (NASDAQ:GMAB) by 27.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 22,204 shares of the company’s stock after buying an additional 4,835 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Genmab A/S were worth $463,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its stake in shares of Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after acquiring an additional 12,654 shares during the period. AIMZ Investment Advisors LLC bought a new position in Genmab A/S during the 4th quarter valued at about $3,525,000. HighTower Advisors LLC purchased a new stake in Genmab A/S in the 3rd quarter worth about $273,000. Verition Fund Management LLC bought a new stake in Genmab A/S in the third quarter worth about $709,000. Finally, FMR LLC boosted its position in shares of Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after buying an additional 33,076 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Truist Financial decreased their price target on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

Genmab A/S Stock Performance

Shares of GMAB opened at $20.20 on Wednesday. The stock has a market capitalization of $13.37 billion, a PE ratio of 11.61, a PEG ratio of 2.65 and a beta of 0.98. The company has a 50 day moving average price of $21.18 and a 200-day moving average price of $22.28. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.02.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities research analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.